MetaCap

Amneal Pharmaceuticals Inc. Class A Company Profile

NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

21.12-0.27 (-1.26%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Amneal Pharmaceuticals at a glance

Amneal Pharmaceuticals Inc. Class A (NASDAQ: AMRX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Bridgewater, NJ. Amneal Pharmaceuticals is led by Mr. Chirag K. Patel and employs about 8,700 people. At a market capitalization of $7.45 billion, it is considered a mid-cap company.

Its SEC Central Index Key (CIK) is 0001723128, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Amneal Pharmaceuticals do?

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Business description based on the company's public filings.

Company information

Legal name
Amneal Pharmaceuticals Inc. Class A
Ticker
NASDAQ: AMRX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Chirag K. Patel
Employees
8,700
Headquarters
400 Crossing Boulevard, Bridgewater, NJ, United States
Phone
908 947 3120
Website
amneal.com
SEC CIK
0001723128
Latest annual report
10-K · Feb 27, 2026

Companies similar to Amneal Pharmaceuticals

AMRX peer companies
CompanyPrice% ChgMarket capCompare
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs AMRX
ALKSAlkermes plc44.94-2.69%$7.55Bvs AMRX
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs AMRX
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs AMRX
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs AMRX
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs AMRX
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs AMRX
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs AMRX

Related